Airway cells from atopic asthmatic patients exposed to ozone display an enhanced innate immune gene profile - 24/12/11
Doi : 10.1016/j.jaci.2011.11.007
Michelle Hernandez, MD a, b 
, Willie June Brickey, PhD c, Neil E. Alexis, PhD a, b, Rebecca C. Fry, PhD d, Julia E. Rager, MS d, Baiming Zhou, MS e, Jenny P.Y. Ting, PhD e, Haibo Zhou, PhD a, e, 
, David B. Peden, MD, MS a, b, c,
, Willie June Brickey, PhD c, Neil E. Alexis, PhD a, b, Rebecca C. Fry, PhD d, Julia E. Rager, MS d, Baiming Zhou, MS e, Jenny P.Y. Ting, PhD e, Haibo Zhou, PhD a, e, , David B. Peden, MD, MS a, b, c, a Center for Environmental Medicine, Asthma and Lung Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC
b Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC
c Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC
d Environmental Sciences & Engineering, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC
e Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC
| M.H. is supported by National Institutes of Health grant KL2RR025746. W.J.B., N.E.A., J.P.Y.T., and D.B.P. are supported by National Institute of Allergy and Infectious Diseases grant U19AI077437. R.C.F. and J.E.R. are supported by grant P30ES010126. This work was also funded by CR 83346301 from the US Environmental Protection Agency. Although the research described in this article has been funded in part by the United States Environmental Protection Agency through cooperative agreement CR833463-01 with the Center for Environmental Medicine, Asthma, and Lung Biology at the University of North Carolina at Chapel Hill, it has not been subjected to the Agency's required peer and policy review, and therefore does not necessarily reflect the views of the Agency and no official endorsement should be inferred. Mention of trade names or commercial products does not constitute endorsement or recommendation for use. |
|
| Disclosure of potential conflict of interest: N. E. Alexis has contracts with Centocor Pharmacueticals, GlaxoSmithKline and MedImmune. D. B. Peden has been a consultant to GlaxoSmithKline and Aquinox Pharmaceuticals and had a contract with MedImmune. J. P. Y. Ting had a 1-year contract with GlaxoSmithKline (Philadelphia). The rest of the authors declare that they have no relevant conflicts of interest. |
© 2011
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 129 - N° 1
P. 259 - janvier 2012 Retour au numéro
Article précédent
- Opposite effects of allergy prevention depending on CD14 rs2569190 genotype in 3 intervention studies
- Marjan Kerkhof, Denise Daley, Dirkje S. Postma, Julie E. Park, Moira Chan Yeung, Alet H. Wijga, Ulrike Gehring, Johan C. de Jongste, Henriëtte A. Smit, Bert Brunekreef, Onno C.P. van Schayck, Allan Becker, Gerard H. Koppelman
- No reason to change the current guidelines on allergy prevention
- Sibylle Koletzko, Birgit Filipiak-Pittroff, Berthold Koletzko, Andrea von Berg, Ursula Krämer, Dietrich Berdel, Joachim Heinrich, German Infant Nutritional Intervention study group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?